Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...
With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.
McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.
The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...
During JPM week, virtual care companies strut their plans to make GLP-1 drugs work harder, cost less
Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...
This advancement offers a promising approach to overcoming the tolerability challenges and adverse effects commonly linked to prolonged GLP-1 drug use ... a GLP-1 agonist marketed by Novo Nordisk ...
a GLP-1 agonist marketed by Novo Nordisk under the brand names Ozempic and Wegovy when administered together but now to potentially sustain these effects after a GLP-1’s discontinuation. “One of the ...
This advancement offers a promising approach to overcoming the tolerability challenges and adverse effects commonly linked to prolonged GLP-1 drug use ... a GLP-1 agonist marketed by Novo Nordisk ...
Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...
GLP-1: Glucagon-like peptide-1; RA: receptor agonist. ACS: Acute coronary syndrome ... result in significant decrease in efficacy of the medication class. LA GLP1-RAs in studies to date appear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback